2021
Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infection
2020
Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma.
Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V. Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 85: 530-534. PMID: 33185999, PMCID: PMC8353543, DOI: 10.1097/qai.0000000000002510.Peer-Reviewed Original ResearchConceptsSetting of HCCFIB-4Receiver-operating characteristic curveHepatocellular carcinomaHCC diagnosisPredictive valueVeterans Aging Cohort StudyEvidence of cirrhosisSetting of HIVAbsence of cirrhosisFIB-4 scoreFibrosis-4 indexIncident hepatocellular carcinomaMedical record reviewPrevalence of cirrhosisAging Cohort StudyCross-sectional studyCharacteristic curveNegative predictive valuePositive predictive valueCirrhosis statusCohort studyMechanisms of carcinogenesisRecord reviewPlatelet count
2017
FIB‐4 stage of liver fibrosis predicts incident heart failure among HIV‐infected and uninfected patients
So‐Armah K, Lim JK, Re V, Tate JP, Chang C, Butt AA, Gibert CL, Rimland D, Marconi VC, Goetz MB, Rodriguez‐Barradas M, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS, Team F. FIB‐4 stage of liver fibrosis predicts incident heart failure among HIV‐infected and uninfected patients. Hepatology 2017, 66: 1286-1295. PMID: 28543215, PMCID: PMC5609079, DOI: 10.1002/hep.29285.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusFibrosis/cirrhosisHIV/HCV statusAdvanced fibrosis/cirrhosisLiver fibrosisCHF eventsHCV statusFIB-4Hepatitis CAdvanced liver fibrosis/cirrhosisIncident CHFCongestive heart failure riskCardiovascular disease risk factorsVeterans Aging Cohort StudyProportional hazards regression modelsLiver fibrosis/cirrhosisIncident CHF eventsRisk of CHFFibrosis-4 indexIncident heart failureDisease risk factorsHeart failure riskAging Cohort StudyCardiovascular disease riskPrevalent cardiovascular disease
2015
Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
Re V, Kallan MJ, Tate JP, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park LS, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR. Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Open Forum Infectious Diseases 2015, 2: ofv109. PMID: 26284259, PMCID: PMC4536329, DOI: 10.1093/ofid/ofv109.Peer-Reviewed Original ResearchEnd-stage liver diseaseHIV/HCV-coinfected patientsRisk of ESLDHIV/HCV patientsHuman immunodeficiency virusFIB-4Antiretroviral therapyESLD riskHCV patientsLaboratory variablesLiver diseaseHuman immunodeficiency virus/hepatitis C virus‐coinfected patientsHepatitis C virus-coinfected patientsLiver-related deathRetrospective cohort studyRisk factor modificationPlatelet ratio indexDecision curve analysisVeterans Health AdministrationHCV treatment decisionsHepatic decompensationHCV treatmentCohort studyCox regressionImmunodeficiency virus
2014
HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function.
So-Armah KA, Chang J, Alcorn C, Lo Re V, Baker JV, Tracy R, Butt AA, Agan BK, Rimland D, Gibert CL, Goetz MB, Oursler KK, Rodriguez-Barradas MC, Kuller LH, Brown ST, Stein JH, Skanderson M, Justice AC, Freiberg MS. HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. Current HIV Research 2014, 12: 50-9. PMID: 25034208, PMCID: PMC4495647, DOI: 10.2174/1570162x1201140716101512.Peer-Reviewed Original ResearchConceptsART initiationHIV infectionHIV infection levelsViral suppressionLongitudinal changesLDL cholesterolPositive HIV antibody testBiomarker measurementsAge-related chronic diseasesAntiretroviral therapy initiationEnd-organ diseaseFIB-4 scoreHIV antibody testWilcoxon signedrank testUninfected veteransVACS-VCFIB-4Therapy initiationHIV levelsHDL cholesterolSerum levelsTotal cholesterolPlatelet countMean ageChronic diseases
2013
Acetaminophen receipt among HIV‐infected patients with advanced hepatic fibrosis
Edelman EJ, Gordon KS, Re V, Skanderson M, Fiellin DA, Justice AC, Team F. Acetaminophen receipt among HIV‐infected patients with advanced hepatic fibrosis. Pharmacoepidemiology And Drug Safety 2013, 22: 1352-1356. PMID: 24285468, PMCID: PMC4164158, DOI: 10.1002/pds.3517.Peer-Reviewed Original ResearchConceptsAdvanced hepatic fibrosisAcetaminophen exposureHCV statusHepatic fibrosisHIV/HCV-coinfected patientsVeterans Aging Cohort StudyAdvanced liver fibrosisAging Cohort StudyAcetaminophen-induced hepatotoxicitySample of HIVCross-sectional associationsPolytomous logistic regressionAlcohol use disorderCross-sectional analysisAcetaminophen prescriptionsAcetaminophen useHIV-monoinfectedFIB-4Cohort studyLiver injuryPlatelet countLiver fibrosisAlanine aminotransferaseHIVPatients
2011
FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients
Park LS, Tate JP, Justice AC, Re V, Lim JK, Bräu N, Brown ST, Butt AA, Gibert C, Goetz MB, Rimland D, Rodriguez-Barradas MC, Dubrow R. FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 2512-2517. PMID: 22028407, PMCID: PMC3237927, DOI: 10.1158/1055-9965.epi-11-0582.Peer-Reviewed Original ResearchConceptsHigh FIB-4C virus infectionFIB-4Hepatocellular carcinomaVirus infectionRisk factorsHigh riskVeterans Affairs Central Cancer RegistryAlcohol abuse/dependencyHIV-1 RNA levelsHepatitis B virus infectionHepatitis C virus infectionVeterans Aging Cohort StudyDevelopment of HCCLow FIB-4Multivariate-adjusted HRNoninvasive laboratory testsAntiretroviral therapy useFIB-4 indexB virus infectionIndependent risk factorHCC risk factorsAging Cohort StudyIncident HCC casesCentral Cancer Registry